Anti-CD30 antibody-based therapy.
The increased expression of CD30 on some neoplasms versus its limited expression on normal tissue makes it an excellent target for antibody-based therapy. Recent studies have shown that anti-CD30 antibodies may serve as signaling molecules as well as mediators of interactions with the immune system. Unmodified anti-CD30 antibodies as well as anti-CD30-based bispecific antibodies, immunotoxins, and radioimmunoconjugates have been examined in preclinical and clinical studies. The data show that anti-CD30-based therapies are promising new treatment modalities for CD30+ neoplasms.
Koon
H B
HB
Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA.
Junghans
R P
RP
D000906:Antibodies / Q000627:therapeutic use*; D018033:Antibodies, Bispecific / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D000922:Immunotoxins / Q000627:therapeutic use; D017730:Ki-1 Antigen / Q000096:biosynthesis* / Q000276:immunology; D008954:Models, Biological; D009369:Neoplasms / Q000628:therapy*; D016499:Radioimmunotherapy / Q000379:methods; D017452:Receptors, IgG / Q000096:biosynthesis / Q000276:immunology
D000906:Antibodies; D018033:Antibodies, Bispecific; D000922:Immunotoxins; D017730:Ki-1 Antigen; D017452:Receptors, IgG